Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2020 Jan;99(1):e18624.
doi: 10.1097/MD.0000000000018624.

Neutropenia Following Intravenous Immunoglobulin Therapy in Adult Patients With Immune Thrombocytopenic Purpura: A Single Center Experience and Literature Review

Affiliations
Free PMC article
Observational Study

Neutropenia Following Intravenous Immunoglobulin Therapy in Adult Patients With Immune Thrombocytopenic Purpura: A Single Center Experience and Literature Review

Sang-Bo Oh et al. Medicine (Baltimore). .
Free PMC article

Abstract

The purpose of this study was to evaluate neutropenia following intravenous immunoglobulin (IVIG) therapy in adults with immune thrombocytopenic purpura (ITP).Our analysis included 88 patients with ITP, who received IVIG from January 2006 to March 2016, at Pusan National University Hospital in Korea. Their white blood cell (WBC) count and absolute neutrophil count (ANC) before and after IVIG treatment were analyzed.Of 88 patients, 24 patients (27.3%) were male, and 64 patients (72.7%) were female. Neutropenia developed in 8 patients (18.7%) after IVIG treatment. In patients with a decrease in WBC count and ANC compared to baseline, median WBC count decreased from 6280/μL to 4530/μL after IVIG therapy, and median ANC decreased from 3840/μL to 2840/μL after IVIG therapy. The neutropenia induced by IVIG had resolved spontaneously after several days, and the mean recovery time was 8.72 days after the completion of the IVIG treatment. During the neutropenic episodes, only one patient developed neutropenic fever, which subsided soon without any treatment.The results of this study suggest that IVIG may cause neutropenia commonly in adults with ITP, and it seems to be transient and self-limited. This study is meaningful as the first report that not only pediatric ITP patients may develop neutropenia post IVIG administration, but also adult patients suffering ITP.

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Similar articles

See all similar articles

References

    1. Gernsheimer T, Stratton J, Ballem PJ, et al. Mechanisms of response to treatment in autoimmune thrombocytopenic purpura. N Engl J Med 1989;320:974–80. - PubMed
    1. Chang M, Nakagawa PA, Williams SA, et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 2003;102:887–95. - PubMed
    1. McMillan R, Nugent D. The effect of antiplatelet autoantibodies on megakaryocytopoiesis. Int J Hematol 2005;81:94–9. - PubMed
    1. Douglas DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002;346:995–1008. - PubMed
    1. Ansari S, Shirali A, Khalili N, et al. Neutropenia following intravenous immunoglobulin therapy in pediatric patients with idiopathic thrombocytopenic purpura. IJBC 2014;6:81–5.

Publication types

Substances

Feedback